For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Viromed Co., Ltd.

Calculating rank

USPTO Granted Patents = 17

% Expired Patents = 23.5

CIPO Patents = 1

EPO Patents = 10

Trademarks = 2

Forward Citations = 111

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Jong-Mook Kim (8 out of 13 patents)

Woong Hahn (5 out of 6 patents)

Sujeong Kim (4 out of 16 patents)

4. Sunyoung Kim (3 out of 38 patents)

5. Eun-Jin Park (3 out of 7 patents)

6. Song Xu (2 out of 6 patents)

7. Seong-Hyun Ho (2 out of 3 patents)

8. Seung Shin Yu (1 out of 6 patents)

9. Jin-A Chae (1 out of 4 patents)

10. Mi Rim Jin (1 out of 6 patents)

11. Hwa-Jun Lee (1 out of 4 patents)

12. Chang-Yuil Kang (1 out of 12 patents)

13. Jun-tae Lee (1 out of 5 patents)

14. Sun-Young Chang (1 out of 29 patents)

15. Sun-Young Kim (1 out of 44 patents)

17 patents: Sort by Forward Citations

1. 10058583 - Herbal compositions for treating neurological diseases and improving memory impairment (2018-08-28),

2. 9963493 - Gene therapy for diabetic neuropathy using an HGF isoform (2018-05-08),

3. 9404090 - Adenovirus producing novel cell line and the use thereof (2016-08-02),

4. 9131722 - [object Object] (2015-09-15),

5. 8716446 - Biopolymer conjugates comprising an interleukin-11 analog (2014-05-06),

6. 8445268 - Her-2/neu DNA vaccine having anti-cancer activity (2013-05-21),

7. 8394426 - Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders (2013-03-12),

8. 8389492 - Lyophilized DNA formulations for enhanced expression of plasmid DNA (2013-03-05),

9. 8338385 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2012-12-25),

10. 8106158 - Compositions and methods for fusion protein separation (2012-01-31),

11. 8105575 - Expression vectors with improved safety (2012-01-31),

12. 7838505 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2010-11-23),

13. 7812146 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2010-10-12),

14. 7745174 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2010-06-29),

15. 7585943 - Compositions and methods for fusion protein separation (2009-09-08),

Company Overview

Viromed Co., Ltd. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative biopharmaceuticals. The company focuses on advanced therapeutic solutions, particularly in the fields of gene therapy and regenerative medicine. With a commitment to addressing unmet medical needs, Viromed leverages cutting-edge technologies to create treatments that aim to improve patient outcomes. Its research initiatives are geared towards harnessing the potential of biological systems to develop effective therapies for various diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

17 Patents

#266 in Seoul

#719 in South Korea

#35,974 in the World

Seoul, South Korea

Viromed Co., Ltd.

Forward Citations = 111

43 inventors:

Jong-Mook Kim (8 out of 13 patents)

Woong Hahn (5 out of 6 patents)

Sujeong Kim (4 out of 16 patents)

4. Sunyoung Kim (3 out of 38 patents)

5. Eun-Jin Park (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Viromed Co., Ltd.. Retrieved from https://idiyas.com/company/viromed-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…